Serum microRNAs levels in primary focal segmental glomerulosclerosis
- PMID: 23463342
- PMCID: PMC3722457
- DOI: 10.1007/s00467-013-2434-7
Serum microRNAs levels in primary focal segmental glomerulosclerosis
Abstract
Background: MicroRNAs (miRNAs, miRs) are involved in most physiological, developmental, and pathological processes. miR-192 and miR-205 are expressed preferentially in the renal cortex and closely relevant to the renal cell biology. In the present study, we aim to measure the serum levels of miR-192 and miR-205 and their correlation with clinicopathological data in patients with primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).
Methods: Fifty-six patients (35 male, 21 female) with idiopathic nephrotic syndrome (FSGS 30, MCD 26) and 20 healthy controls were enrolled in the study. We quantified the serum levels of miR-192 and miR-205 in patients with FSGS and MCD by RT-qPCR.
Results: Patients with FSGS had higher serum levels of miR-192 and miR-205 than those with MCD (324.49 ± 42.74 fmol/l versus 90.19 ± 27.14 fmol/l, p < 0.01, 2.25 ± 0.69 fmol/l versus 0.60 ± 0.51 fmol/l, p < 0.01, respectively). The level of miR-192 was positively correlated with the proteinuria in patients with FSGS and MCD (r = 0.62, p < 0.001, r = 0.84, p < 0.001, respectively). Similarly, the level of miR-205 was positively correlated with the proteinuria in patients with FSGS (r = 0.54, p = 0.002). In addition, the serum level of miR-192 was significantly correlated with the degree of interstitial fibrosis in patients with FSGS (r = 0.342, p < 0.05).
Conclusions: miR-192 and miR-205 have the potential as markers to differentiate FSGS from MCD.
Figures
Similar articles
-
Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.Eur J Clin Invest. 2015 Apr;45(4):394-404. doi: 10.1111/eci.12420. Eur J Clin Invest. 2015. PMID: 25682967 Free PMC article.
-
Minimal change disease and idiopathic focal segmental glomerulosclerosis in adults. A quantitative study.Pol J Pathol. 1996;47(4):209-14. Pol J Pathol. 1996. PMID: 9097714 Clinical Trial.
-
In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.PLoS One. 2020 Nov 4;15(11):e0241745. doi: 10.1371/journal.pone.0241745. eCollection 2020. PLoS One. 2020. PMID: 33147279 Free PMC article.
-
Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.Expert Opin Investig Drugs. 2018 Nov;27(11):839-879. doi: 10.1080/13543784.2018.1540587. Epub 2018 Oct 30. Expert Opin Investig Drugs. 2018. PMID: 30360670 Review.
-
Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020.Am J Kidney Dis. 2020 Jun;75(6):955-964. doi: 10.1053/j.ajkd.2019.12.019. Epub 2020 Apr 21. Am J Kidney Dis. 2020. PMID: 32331832 Review.
Cited by
-
Study on the Mechanism of circRNA Regulating the miRNA Level in Nephrotic Syndrome.Evid Based Complement Alternat Med. 2022 Jul 11;2022:3729995. doi: 10.1155/2022/3729995. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35859997 Free PMC article. Retracted.
-
Pathogenic Role of MicroRNA Dysregulation in Podocytopathies.Front Physiol. 2022 Jun 29;13:948094. doi: 10.3389/fphys.2022.948094. eCollection 2022. Front Physiol. 2022. PMID: 35845986 Free PMC article. Review.
-
Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.Clin Kidney J. 2020 Aug 11;14(2):482-491. doi: 10.1093/ckj/sfaa110. eCollection 2021 Feb. Clin Kidney J. 2020. PMID: 33623672 Free PMC article. Review.
-
MicroRNAs as Biomarkers for Nephrotic Syndrome.Int J Mol Sci. 2020 Dec 23;22(1):88. doi: 10.3390/ijms22010088. Int J Mol Sci. 2020. PMID: 33374848 Free PMC article. Review.
-
The Role of MicroRNAs in Selected Forms of Glomerulonephritis.Int J Mol Sci. 2019 Oct 11;20(20):5050. doi: 10.3390/ijms20205050. Int J Mol Sci. 2019. PMID: 31614644 Free PMC article. Review.
References
-
- Nezhad ST, Momeni B, Basiratnia M. Glomerular malondialdehyde levels in patients with focal and segmental glomerulosclerosis and minimal change disease. Saudi J Kidney Dis Transpl. 2010;21:886–891. - PubMed
-
- Gulati S, Sengupta D, Sharma RK, Sharma A, Gupta RK, Singh U, Gupta A. Steroid resistant nephrotic syndrome: role of histopathology. Indian Pediatr. 2006;43:55–60. - PubMed
-
- Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334:878–883. doi: 10.1056/NEJM199604043341402. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
